U-500R Insulin In Type 2 Diabetes With Severe Insulin Resistance Via Omnipod

• Status: Completed
• Trial end date: 2009-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Patients with Type 2 diabetes and severe insulin resistance with very large insulin requirements who have failed all previous insulin regimens using non-concentrated forms of insulin (U100 insulin formulations) will receive 5X concentrated insulin (U500 regular insulin)infused via insulin pump.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mountain Diabetes and Endocrine Center
• Treatments: Insulin; Insulin, Globin Zinc

Criteria

Inclusion Criteria:

• Type 2 diabetes on stable insulin regimen with or without oral agents for at least 3 months

• HbA1c > 7%

• No significant cardiovascular, renal or other serious medical diseases

Exclusion Criteria:

• HbA1c < 7%

• Chronic renal, hepatic, cardiovascular, or other serious medical illness

• Females of childbearing age not using adequate contraception

• Use of GLP mimetic